The molecular sub-type of breast cancer is a predictor of response to neo-adjuvant chemotherapy, with cancers of triple negative and HER2-positive sub-types more commonly obtaining complete pathologic responses than ER-positive cancers. This evidence concerns the gene ERBB2 and breast carcinoma.